Research paper

Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol

Louise Sigfrid,*, Thomas M. Drake, Ellen Pauley, Edwin C. Jesudason, Piero Olliaro, Wei Shen Lim, Annelies Gillesen, Colin Bern, David J. Lowe, Joanne McPeake, Nazir Lone, Daniel Munblit, Muge Cevik, Anna Casey, Peter Bannister, Clark D. Russell, Lynsey Goodwin, Antonio Ho, Lance Turtle, Margaret E. O'Hara, Claire Hastie, Chloe Donohue, Rebecca G. Spencer, Cara Donegan, Alison Gumery, Janet Harrison, Hayley E. Hardwick, Claire E. Hastie, Gail Carson, Laura Merson, J. Kenneth Baillie, Janet T. Scott, ISARIC global follow-up working group, ISARIC4C investigators

* Clinical Research Fellow, Public Health Specialist, ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK
** Clinical Research Fellow, Centre for Medical Informatics, University of Edinburgh, Edinburgh, UK
† Medical Student, University of Edinburgh Medical School, Edinburgh, UK
‡ Consultant in Rehabilitation Medicine, NHS Lothian, Edinburgh, UK
§ Professor of Poverty Related Infectious Diseases, ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK
¶ Honorary Professor of Respiratory Medicine, Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust and University of Nottingham, UK
‖ Senior Clinical Trial Nurse, ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK
¶¶ Professor of Cardiology and Imaging, Institute of Cardiovascular and Medical Sciences, University of Glasgow
Á Nurse Consultant in Clinical Research, School of Medicine, Dentistry and Nursing, University of Glasgow, UK
Â Senior Clinical Lecturer in Critical Care, Usher Institute, University of Edinburgh, Edinburgh, UK
ÁÁ Professor of Paediatrics, Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
ÁÁÁ Clinical Senior Lecturer, Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK
ÁÁÁÁ Medical Student, Brighton and Sussex Medical School, Brighton, UK
ÁÁÁÁÁ Clinical Lecturer in Infectious Diseases, Centre for Inflammation Research, University of Edinburgh, UK
ÁÁÁÁÁÁ Specialist Registrar in Infectious Diseases and General Internal Medicine, Tropical and Infectious Diseases Unit, North Manchester General Hospital, Delaunays Rd, Manchester, UK
ÁÁÁÁÁÁÁ Clinical Research Fellow, National Institute of Health Research (NIHR) Health Protection Research Unit in emerging and zoonotic infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK
ÁÁÁÁÁÁÁÁ Clinical Senior Lecturer/Consultant in Infectious Diseases, MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
ÁÁÁÁÁÁÁÁÁ Senior Clinical Lecturer, NIHR Health Protection Research Unit in emerging and zoonotic infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK
ÁÁÁÁÁÁÁÁÁÁ Consultant in Infectious Disease, Tropical and Infectious Disease Unit, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
ÁÁÁÁÁÁÁÁÁÁÁ Patient-advocate, Long COVID Support, Birmingham, UK
ÁÁÁÁÁÁÁÁÁÁÁÁ Trials Coordinator, Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK
ÁÁÁÁÁÁÁÁÁÁÁÁÁ Project Administrator, Institute of Infection, Veterinary and Ecological Sciences (IVES), University of Liverpool, Liverpool, UK
ÁÁÁÁÁÁÁÁÁÁÁÁÁÁ Project Administrator, Institute of Infection, Veterinary and Ecological Sciences (IVES), University of Liverpool, Liverpool, UK
ÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ Data Base Developer, National Institute of Health Research (NIHR) Health Protection research Unit in Emerging and Zoonotic Infections, Liverpool, UK
ÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ Institute of Infection and Global Health, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
ÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ Project Manager, National Institute of Health Research (NIHR) Health Protection research Unit in Emerging and Zoonotic Infections, Liverpool, UK
ÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ Lecturer in Public Health, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
ÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ Head, ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK
ÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ Head of Data, ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK
ÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ Senior Clinical Research Fellow, Roslin Institute, University of Edinburgh, Edinburgh, UK
ÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ Prof. of Experimental Medicine, National Heart and Lung Institute, Imperial College, London UK
ÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ Director Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK
ÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁÁ Wellcome Clinical Research Career Development Fellow, Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK

Protocol registration number: osf.io/c5rw3/
EuroQol ID: 37035

Correspondence to: Dr Janet T Scott, MRC-University of Glasgow Centre for Virus Research, Garscube Estate, Glasgow, G61 1QH. Phone: +44 (0)141 339 4017
E-mail address: janet.scott@glasgow.ac.uk (J.T. Scott)

https://doi.org/10.1016/j.lanepe.2021.100186
2666-7762/© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
ABSTRACT

Background: This study sought to establish the long-term effects of Covid-19 following hospitalisation.

Methods: 327 hospitalised participants, with SARS-CoV-2 infection were recruited into a prospective multicentre cohort study at least 3 months post-discharge. The primary outcome was self-reported recovery at least ninety days after initial Covid-19 symptom onset. Secondary outcomes included new symptoms, disability (Washington group short scale), breathlessness (MRC Dyspnoea scale) and quality of life (EQ5D-5L).

Findings: 55% of participants reported not feeling fully recovered. 93% reported persistent symptoms, with fatigue the most common (83%), followed by breathlessness (54%). 47% reported an increase in MRC dyspnoea scale of at least one grade. New or worse disability was reported by 24% of participants. The EQ5D-5L summary index was significantly worse following acute illness (median difference 0.1 points on a scale of 0 to 1, IQR: -0.2 to 0.0). Females under the age of 50 years were 3.45 times less likely to report feeling recovered (adjusted OR 5.09, 95% CI 1.64 to 15.74), were more likely to have greater disability (adjusted OR 4.22, 95% CI 1.12 to 15.94), twice as likely to report worse fatigue (adjusted OR 2.06, 95% CI 0.81 to 3.31) and seven times more likely to become more breathless (adjusted OR 7.15, 95% CI 2.24 to 22.83) than men of the same age.

Interpretation: Survivors of Covid-19 experienced long-term symptoms, new disability, increased breathlessness, and reduced quality of life. These findings were present in young, previously healthy working age adults, and were most common in younger females.

Funding: National Institute for Health Research, UK Medical Research Council, Wellcome Trust, Department for International Development and the Bill and Melinda Gates Foundation.

© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

1. Introduction

Our understanding of long-term outcomes after acute Covid-19 remains limited. It is becoming increasingly evident that some patients who have had acute Covid-19 go on to experience persistent symptoms, known as long-Covid or post-Covid syndrome [1]. Several studies in hospitalised and community settings have identified that those with Covid-19 frequently develop long-term symptoms and a range of sequelae affecting the kidneys, lungs and heart [1–5]. These symptoms appear to overlap with other post-viral syndromes and with the challenges faced by patients recovering from other critical illness with post-intensive care syndrome (PICS), such as muscle weakness, fatigue, and sleep disturbance [6–10]. Yet, understanding the impact Covid-19 has on patient reported outcome measures, including quality of life, has not yet been fully characterised [11].

Many clinical trials or studies that aim to characterise the immediate course of Covid-19 have used mortality as a primary outcome [12,13]. This has demonstrated that patients in older age groups and those who have pre-existing comorbidities are at higher risk of dying from the disease [14–17]. Nonetheless, most people with Covid-19 will survive the initial acute infection and data on what happens to these individuals in the long-term are lacking. The large number of people affected by Covid-19 and the growing evidence of long-term sequelae highlights the importance for policy makers, society and healthcare systems to understand the difficulties faced by those suffering from long-Covid [4,18,19]. Understanding the burden of disease, and who is at greatest risk of developing long-term complications, may help to target preventative strategies and provide effective support for affected individuals to improve Covid-19 outcomes and reduce risk of widening health inequalities by inadequate rehabilitation and recovery support. Identifying which patient groups are most likely to be affected could provide data to guide policy and aid future research to identify disease mechanisms, and to formulate and test new interventions.

The objective of this study was to characterise long-term patient reported outcomes in individuals who survived hospitalisation for
Covid-19, in those who engaged with post hospital follow-up, using the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol (CCP-UK) and follow-up protocol [20].

2. Methods

2.1. Study design and setting

The ISARIC WHO Clinical Characterisation Protocol (CCP) was first developed by international consensus in 2012 to respond to any emerging or re-emerging pathogen of public health interest [21]. It was activated in the UK in response to the SARS-CoV-2 pandemic on 17th January 2020. Study information including the CCP-UK and post hospital follow-up protocol, standardised case report forms, study information and consent forms, are available on the ISARIC4C.net website. Hospitals providing acute care throughout the United Kingdom were eligible to enrol participants into the study. This analysis is reported in line with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [22].

2.2. Participants

Patients aged 18 years and over, admitted to hospital between 17th January to 5th October 2020 with confirmed or highly suspected SARS-CoV-2 infection at 31 centres, who consented to be contacted for post hospital follow-up and were discharged at least 90 days ago were eligible for inclusion. Participants experienced post-Covid sequelae without formal treatment as management pathways for long Covid were not available at this time. Confirmation of SARS-CoV-2 was by reverse-transcriptase polymerase chain reaction (RT-PCR). Individuals with clinically diagnosed highly suspected, Covid-19 were also eligible for inclusion, given that SARS-CoV-2 was an emergent pathogen in the earlier stages of the pandemic and laboratory confirmation was dependent on local availability of PCR testing.

2.3. Variables

Patient questionnaires for adults were developed by a multidisciplinary team of researchers, clinicians and psychologists through a series of meetings and e-mail iterations [21]. These were piloted in three countries before being finalised. The UK version was piloted with patients at sites in Liverpool and Glasgow. Patient questionnaires were designed to allow self-assessment via post, or clinician-led follow up via telephone, or in outpatient clinic, to support wide dissemination. All surviving patients who consented to be contacted following discharge, and for whom a valid address or phone number were provided, were contacted. Questionnaires were posted from the Outbreak Laboratory coordinating centre at the University of Liverpool, UK, with a prepaid, self-addressed envelope for returning the questionnaire. A combination of postal and telephone follow-up was used to improve response rates. Those who did not respond by post and who had a valid phone number were followed up by telephone or in outpatient clinic by local study investigators. Participants completed one questionnaire as part of this study, so there were no repeat measures. Data from responses were entered onto a Research Electronic Capture (REDCap) Database system hosted at the University of Oxford and linked with data documented during the admission with acute Covid-19 for the analysis.

Explanatory variables at the time of hospital admission, including age, sex, pre-existing comorbidities, and treatment received during the hospital admission were recorded. Maximum severity of Covid-19 during the acute hospital admission with Covid-19 was classified using the WHO COVID-19 ordinal severity scale [23]. This scale comprised of 4 levels of severity which were relevant to our in-hospital cohort; level 3 - did not receive supplemental oxygen, level 4 - received supplemental oxygen, level 5 - received high flow oxygen or NIV non-invasive ventilation (HFNC, NIV), and levels 6 and 7 - received invasive mechanical ventilation or admission to critical care [23]. We also used the WHO severity scale to account for in-hospital severity in our modelling approach [23,24].

2.4. Outcomes

The primary outcome was self-reported recovery at 3 to 12 months following initial Covid-19 symptoms. Secondary outcomes included persistent or new symptoms, new or worsened disability assessed using the Washington Disability Group (WG) Short Form [25], breathlessness measured using the Medical Research Council (MRC) dyspnoea scale [26], fatigue measured on a 1 to 10 visual analogue scale (VAS) where zero is no fatigue and ten is worst possible fatigue, and quality of life using the EuroQol® EQ5D-5L instrument (Supplementary Appendix 2) [27]. The MRC dyspnoea scale was developed to grade the extent of breathlessness on daily activities [26]. This 5-point scale measures perceived respiratory disability, with 1 being no breathlessness and 5 being unable to undertake activities of daily living due to breathlessness [26]. The WG Short Set tool includes six questions on functioning (vision, hearing, mobility, cognition, self-care, communication) [25]. These questions reflect a bio-psychosocial model of disability by describing level of disability and probe aspects of disability which may limit an individual’s participation in society. This tool has been shown to detect the majority of disabilities and is standardised for use globally [25]. The EuroQol®EQ5D-5L tool was used to measure psychosocial health and quality of life [27]. The tool covers five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The person indicates his/her health state for each of the five dimensions. To compare the change in EQ5D-5L at the time of post-hospital follow-up to before Covid-19 onset, we asked patients the same questions contained in the EQ5D-5L with the tense altered to ask specifically about pre-Covid-19 state.

2.5. Statistical methods

Categorical data were summarised as frequencies and percentages, and continuous data as median, alongside the corresponding interquartile range (IQR) presented as the 25th and 75th centile values. To test for differences across comparison groups in categorical data, we used Fisher’s exact test and for continuous data, used the Wilcoxon rank-sum test for two-sample testing and Kruskal-Wallis where there were more than 2 groups. Analysis of symptom co-occurrence was done using the Jaccard similarity index and represented visually as heatmaps with dendrograms constructed from complete hierarchical clustering results (where 0 is no co-occurrence and 1 is perfect co-occurrence). We then identified clusters of symptoms based upon the hierarchical dendrograms and clusters that were seen on the heatmap.

For disability, breathlessness, and EQ5D-5L index (health state), we calculated the change in value reported by participants before onset of their Covid-19 illness compared to the follow up assessment. For health state at the follow up assessment, we used the EQ5D-5L with the English standardised valuation study protocol (EQ-VT) value set, developed by the EuroQol group on the composite time trade-off (cTTO) valuation [27]. Overall changes in summary health index, before and after Covid-19 onset, were summarised for the cohort using the Paretian Classification of Health Change (PCHC) method [28,29]. Summary EQ5D-5L indices and change in summary EQ5D-5L index were measured on a scale of 0 to 1, with 1 being perfect health and 0 being worst health imaginable. We calculated both the overall estimates and estimates for individual EQ5D-5L dimensions. As a sensitivity analysis, to identify the impact of the presence of a positive SARS-CoV-2 PCR test, we excluded those participants who did not have a positive PCR test reported. We then looked at the outcomes
and ran the same models for the whole cohort in this subgroup to ensure there was no change in the direction or magnitude of the effect.

We created models to adjust for age, sex, presence of comorbidities and in-hospital severity of Covid-19, according to the maximum level of respiratory support that was required. Multilevel logistic regression was used for binary outcomes, and linear regression models were used for continuous outcomes. In both model types, we adjusted for the effects of explanatory variables using fixed-effects and centre by including a random-effects term. For all models, variable selection was performed based on clinical plausibility, and final models were selected based on clinical relevance guided by minimisation of the Akaike information criterion (AIC). Variables were only included in the model if they were present during the first hospital admission for Covid-19. All models were checked for first order interactions and any meaningful interactions were retained and incorporated as dummy variables. Effect estimates are presented as odds ratios for binary outcomes or mean differences for continuous outcomes, along the corresponding 95% confidence interval (95% CI).

Statistical analyses were performed using R version 3.6.3 (R Foundation for Statistical Computing, Vienna, AUT) with the tidyverse, eqSd and Hmisc packages. Statistical significance was taken at the level of P < 0.05.

2.6. Public and patient involvement

This was an urgent public health research study in response to a public health emergency of international concern. Patients and the public were therefore not involved in the design, of the acute phase rapid response research. However, patients and people living with long Covid were involved in the design, conduct and interpretation of the follow up study. The follow up data collection survey and associated patient information was informed by the founding members of the Long Covid support group, who themselves are living with long Covid. The survey was also pilot in several settings in the UK with patients affected by Covid-19 from different demographics, and feedback incorporated into the final version. This included suggestions on the data on symptoms collected and the way questions were asked as well as on the patient information. The results and interpretation of the findings and final manuscript were informed by members of the Long Covid support group.

2.7. Role of the funding source

The study sponsors and funders had no role in the study design, collection, analysis, interpretation of data, writing of the report, or the decision to submit the article for publication. Investigators were independent from funders and the authors have full access to all of the data, including any statistical analyses and tables.

3. Results

Of the 2150 eligible people in the CCP-UK study who were discharged from their acute admission alive, 40% (862/2150) provided consent to be contacted for follow-up. Of these, 97.8% (843/862) were contacted. From these 843 people, 97% (824/843) were 18 or over and 53% (443/824) completed the follow-up questionnaire. Finally, of respondents 73% (327/443) responded 90 days or more after symptom onset. Included participants completed the follow-up questionnaire through self-assessment (71% 234/327), telephone (24.5% 80/327) or in outpatient clinic (4.0% 13/327). The median follow-up time from symptom onset was 222 days (IQR: 189 to 269 days, range: 112 to 343 days, Table 1).

3.1. Participant characteristics

Table 1 shows the characteristics of participants who responded. The majority of participants were male (58.7%, 192/327), with a median age of 59.7 (25th centile 51.7 to 75th centile 67.7) years and of white ethnicity (81.0%, 265/327, Table 1). Asthma (19.9%, 65/327) and diabetes (19.0%, 62/327) were the most common comorbidities (Table 1). 28% (92/327) received invasive mechanical ventilation. Compared with the study population who were contacted and did not respond, respondents were significantly more likely to be of white ethnicity (81.0%, 265/327 participants versus 66.6%, 311/444 of non-respondents), were more likely to be ex-smokers (28.1%, 92/327 participants versus 24.7% 123/497 of non-respondents) and were more likely to have been admitted to critical care (39.8% 130/327 in participants versus 26.8% 133/497 in non-respondents, Supplementary Table 1).

3.2. Outcomes and symptoms

Of 327 participants, 54.7% (179/327) did not feel they had fully recovered at the time of follow-up. At the univariable level, there were no associations between not feeling recovered and the risk factors of age, sex, ethnicity, and comorbidities (Table 1) but we found patients with a higher severity of acute disease were significantly more likely not to feel recovered. Persistent or new symptoms were reported by 93.3% (305/327) participants (Table 2). The most frequently reported symptoms were fatigue 82.8% (255/308), shortness of breath 53.5% (175/327), and problems sleeping 46.2% (151/327, Fig. 2A).

A heatmap and dendrogram of symptom co-occurrence identified two major clusters of symptoms (Fig. 2B); a fatigue, myalgia and sensorineural deficits cluster and an olfactory, appetite and urinary cluster (loss of smell, loss of taste, difficulty passing urine, weight loss and loss of appetite). Within the fatigue, myalgia and sensorineural deficits cluster, there was a distinct minor cluster affecting movement (muscle pain, joint pain, balance and limb weakness).

In addition to symptomatic breathlessness, 46.8% (153/327) of participants reported increased breathlessness compared to their pre-Covid-19 baseline. Overall, change in breathlessness was not affected by age or number of comorbidities (Fig. 3), but was significantly higher in females compared to males (41.7%, 80/192 in males versus 54.1% 73/135 in females). Of participants with a pre-Covid-19 MRC grade 1, 34.0% (73/215) reported an increase to grade 2, and 25.6% (55/213) reported an increase to grades 3-5 at time of post-hospital follow-up (Fig. 4A to 4C). Proportionally, those who were admitted to critical care were more likely to have a higher MRC dyspnoea grade at the time of post hospital follow-up.

Overall, intensity of fatigue was unrelated to age or disease severity in hospital (Fig. 3, Table 2), but females were found to have significantly increased levels of fatigue compared with males (median fatigue 0-10 VAS score, males 4.0, IQR 2.0 to 6; versus females 6.0, IQR 2.0 to 7.0, Supplementary Table 2, Supplementary Figure 1).

New or worsened disability in at least one Washington Group domain was experienced by 24.2% (79/327). This did not change by in-hospital Covid-19 severity (Table 2) or comorbidities (Fig. 3). Females reported a greater number of new or worsened disabilities compared to males (20.3%, 39/192 in males compared with 29.6%, 40/135 in females, Supplementary Table 2). The most affected domain was walking and mobility (33.3% 109/327 new mild or worsened disability, 6.4% 21/327 new moderate or worsened disability and 0.3% 1/327 new severe or worsened disability, Supplementary Table 3), followed by memory and concentration (30.0% 90/327 new mild or worsened disability, 9.8% 32/327 new moderate or worsened disability). There were significant differences in domains affected by sex, with females reporting significantly higher levels of visual disabilities (12.0% 23/192 new mild or
worsened disability for males versus 25.2% 34/135 new mild or worsened disability for females, Supplementary Table 3), higher levels of walking disability (28.6% 55/192 new mild or worsened disability for males versus 40.0% 54/135 new or worsened mild disability for females; 5.6% 11/192 new moderate or worsened disability for males versus 7.4% 10/327 new moderate or worsened disability for females) and memory disability (27.1% 52/192 new mild or worsened disability for males versus 34.1% 46/135 new mild or worsened disability for females; 7.3% 14/192 new moderate or worsened disability for males versus 13.3% 18/135 new moderate or worsened disability for females, Supplementary Table 4).

Overall summary EQSD-5L index was 10% lower overall following Covid-19 (median difference -0.1 points, -0.2 25th centile to 0.07 75th centile, Table 2). This change was independent of age or comorbidities (Fig. 3). The EQSD-5L dimensions for which most participants reported worsening were usual activities (38.9%, 121/311), anxiety/depression (37.6%, 117/311), and pain/discomfort (37.6%, 117/311) (Supplementary Table 5). Female sex was significantly associated with increased problems in the usual activity, pain or discomfort and anxiety and depression domains (Supplementary Table 6).

3.3. Predictors of long-term Covid-19 outcomes

Using multilevel regression models, we adjusted for the effects of age by sex (as this was identified as a significant interaction and retained in our models), the presence of comorbidity and initial in-hospital severity of Covid-19. This generated 6 groups; Males under 50 (34/327), males between 50 and 69 (114/327), males 70 and over (44/327), females under 50 (36/327), females between 50 and 69 (81/327), and females 70 and over (18/327).
For the primary outcome of self-reported overall recovery, females under 50 were 5 times less likely to feel fully recovered (Fig. 4). Similarly, those who received invasive mechanical ventilation were 3.6 times less likely to feel fully recovered (Fig. 4). For the secondary outcomes, age did not appear to be associated with better or worse long-term outcomes (Table 3). Females under 50 were more likely than men to experience persistent fatigue and seven times more likely to experience greater breathlessness, twice as likely to develop new disability and had a significantly poorer health state (EQ5D-5L), all of which persisted in adjusted analyses (Table 3). Participants with one or more comorbidities were more likely to experience greater fatigue, disability, and a poorer health state (EQ5D-5L).

To explore these findings further, we then looked to see if there were any differences in comorbidity or in-hospital disease severity by sex. We found males were significantly more likely to have greater comorbidity (Supplementary Table 8) and more severe in hospital disease (Supplementary Table 9). When we performed a sensitivity analysis for our overall findings, this time excluding patients who did not have a positive SARS-CoV-2 PCR test. The results of these sensitivity analyses (Supplementary Tables 10 and 11), show no effect of SARS-CoV-2 positivity on our estimates for long-term outcomes.

### Table 1
Characteristics of participants who responded

| Characteristic                      | Recovered or unsure | Does not feel fully recovered | Missing | p-value |
|-------------------------------------|---------------------|------------------------------|---------|---------|
| Total N (%)                         | 144 (44*0)          | 179 (54.7)                   | 4 (1.2) | 0.089   |
| **Age**                             |                     |                              |         |         |
| Median (IQR)                        | 60 (53.2 to 69.8)   | 59 (50.3 to 66.7)            | 54 (48.2 to 58.5) | 0.089   |
| Under 50                            | 26 (37.1)           | 43 (61.4)                    | 1 (1.4) |         |
| 50 to 69                            | 83 (42.6)           | 109 (55.9)                   | 3 (1.5) |         |
| Over 70                             | 35 (56.5)           | 27 (43.5)                    | 0 (0.0) |         |
| **Sex at Birth**                    |                     |                              |         |         |
| Male                                | 87 (45.3)           | 103 (53.6)                   | 2 (1.0) | 0.683   |
| Female                              | 57 (42.2)           | 76 (56.3)                    | 2 (1.5) |         |
| **Ethnicity**                       |                     |                              |         |         |
| White                               | 115 (43.4)          | 147 (55.5)                   | 3 (1.1) | 0.206   |
| South Asian                         | 2 (25.0)            | 6 (75.0)                     | 0 (0.0) |         |
| East Asian                          | 3 (75.0)            | 1 (25.0)                     | 0 (0.0) |         |
| Black                               | 10 (66.7)           | 5 (33.3)                     | 0 (0.0) |         |
| Other Ethnic Minority               | 10 (47.6)           | 10 (46.7)                    | 1 (4.8) |         |
| **Smoking**                         |                     |                              |         |         |
| Never Smoked                        | 84 (47.7)           | 90 (51.1)                    | 2 (1.1) | 0.892   |
| Current Smoker                      | 4 (57.1)            | 3 (42.9)                     | 0 (0.0) |         |
| Former Smoker                       | 43 (46.7)           | 47 (51.1)                    | 2 (2.2) |         |
| **Diabetes**                        |                     |                              |         |         |
| No                                  | 112 (44.1)          | 138 (54.3)                   | 4 (1.6) | 0.972   |
| Yes                                 | 27 (43.5)           | 35 (56.5)                    | 5 (4.2) |         |
| **Obesity (as defined by clinical staff)** |             |                              |         |         |
| No                                  | 116 (45.7)          | 136 (53.5)                   | 2 (0.8) | 0.291   |
| Yes                                 | 20 (35.7)           | 34 (60.7)                    | 2 (3.6) |         |
| **Chronic cardiac disease**         |                     |                              |         |         |
| No                                  | 119 (43.8)          | 149 (54.8)                   | 4 (1.5) | 1.000   |
| Yes                                 | 20 (45.5)           | 24 (54.5)                    | 0 (0.0) |         |
| **Chronic pulmonary disease (not asthma)** |             |                              |         |         |
| No                                  | 126 (43.4)          | 160 (55.2)                   | 4 (1.4) | 0.592   |
| Yes                                 | 12 (52.2)           | 11 (47.8)                    | 0 (0.0) |         |
| **Asthma (physician diagnosed)**    |                     |                              |         |         |
| No                                  | 114 (45.2)          | 135 (53.6)                   | 3 (1.2) | 0.410   |
| Yes                                 | 25 (38.5)           | 39 (60.0)                    | 1 (1.5) |         |
| **Chronic kidney disease**          |                     |                              |         |         |
| No                                  | 131 (44.0)          | 163 (54.7)                   | 4 (1.3) | 1.000   |
| Yes                                 | 8 (44.4)            | 10 (55.6)                    | 0 (0.0) |         |
| **Malignant neoplasm**              |                     |                              |         |         |
| No                                  | 136 (44.4)          | 166 (54.2)                   | 4 (1.3) | 1.000   |
| Yes                                 | 4 (40.0)            | 6 (60.0)                     | 0 (0.0) |         |
| **Rheumatologic disorder**         |                     |                              |         |         |
| No                                  | 131 (45.2)          | 155 (53.4)                   | 4 (1.4) | 0.334   |
| Yes                                 | 8 (33.3)            | 16 (66.7)                    | 0 (0.0) |         |
| **ISABIC4C Mortality Score (predicted in hospital mortality)** | | | | |
| Median (IQR)                        | 7 (3.5 to 9.9)      | 6 (4.0 to 9.0)               | 5 (5.0 to 6.0) | 0.648   |
| **Severity**                        |                     |                              |         |         |
| Scale 3 (did not receive supplemental oxygen) | 34 (50.0) | 33 (48.5) | 1 (1.5) | 0.001   |
| Scale 4 (received supplemental oxygen) | 63 (53.4) | 53 (44.9) | 2 (1.7) |         |
| Scale 5 (received HFNC or NIV)      | 22 (44.9)           | 27 (55.1)                    | 0 (0.0) |         |
| Scale 6 or 7 (received invasive mechanical ventilation or critical care) | 25 (5.7) | 66 (71.7) | 1 (1.1) |         |
| **Critical care admission**         |                     |                              |         |         |
| Ward level care only                | 99 (50.3)           | 96 (48.7)                    | 2 (1.0) | 0.008   |
| Admitted to Critical Care           | 45 (34.6)           | 83 (63.8)                    | 2 (1.5) |         |
| **Length of stay (days)**           |                     |                              |         |         |
| Median (IQR)                        | 8 (5.0 to 13.0)     | 11 (6.2 to 25.0)             | 4 (3.0 to 7.8) | <0.001 |
| Median (IQR)                        | 221 (190.0 to 245.0)| 224 (188.0 to 292.0)         | 210.0 (194.2 to 218.5) | 0.419 |
| **Time from symptoms to completing survey (days)** | | | | |
| Median (IQR)                        | 200 (177.0 to 230.0)| 199.0 (161.0 to 268.0)       | 195.0 (178.0 to 208.2) | 0.846   |

HFNC – High flow nasal cannulae, NIV – Noninvasive ventilation, IQR – Interquartile range, presented as 25th to 75th centiles. Numbers are presented as N (%), unless otherwise denoted as a continuous variable.
4. Discussion

We found high rates of long-term symptoms and poor long-term outcomes, which were present several months after hospitalisation for Covid-19. This has implications for planning of care and rehabilitation pathways. These patients may present to multiple specialities within the health care system unless coordinated by a dedicated long Covid service. The range of syndromes identified highlights a need for long Covid clinics to triage patients for further comprehensive diagnostics, based on symptom cluster, including specialist imaging, for assessing underlying aetiology to inform treatment and improve outcomes. Females under 50, and those with severe acute disease

![Fig. 2. Proportion of new or persistent symptoms occurring (Fig. 2A) and their co-occurrence with each other (Fig. 2B).](image-url)

For Figure 2A, fatigue is coloured in green as this outcome was derived from the fatigue visual analogue outcome, where a fatigue rating of 2 or greater was considered as the presence of the fatigue symptom (see Supplementary Table 7 for raw values). Erectile dysfunction affected 23.4% (45/192) of males included, not shown as Figure 2A presents data for any sex. For Figure 2B, the Jaccard similarity index was calculated and presented as intensity of red colour, with 0 (white) being no co-occurrence and 1 (bright red) being always co-occuring.

![Table 2](image-url)

Long-term outcomes by severity of acute Covid-19

| Scale 3 (did not receive supplemental oxygen) | Scale 4 (received supplemental oxygen) | Scale 5 (received HFNC or NIV) | Scale 6 or 7 (received invasive mechanical ventilation or critical care) | p-value |
|---------------------------------------------|----------------------------------------|-------------------------------|-------------------------------------------------|---------|
| Total N (%)                                 |                                        |                               |                                                 |         |
| Self-reported overall recovery              |                                        |                               |                                                 |         |
| Feels fully recovered                       | 68 (20.8)                              | 118 (36.1)                    | 49 (15.0)                                       | 92 (28.1) |         |
| Does not feel fully recovered               | 21 (30.9)                              | 34 (28.8)                     | 11 (22.4)                                       | 17 (18.5) | 0.006   |
| Not sure recovered                          | 13 (19.1)                              | 29 (24.6)                     | 11 (22.4)                                       | 8 (8.7)  |         |
| (Missing)                                   | 1 (1.5)                                | 2 (1.7)                       | 0 (0.0)                                         | 1 (1.1)  |         |
| New or persistent symptoms                  | 3 (4.4)                                | 9 (7.6)                       | 6 (12.2)                                        | 4 (4.3)  | 0.268   |
| No new or persistent symptoms               | 65 (95.6)                              | 109 (92.4)                    | 43 (87.8)                                       | 88 (95.7) |         |
| New or persistent symptoms                  |                                        |                               |                                                 |         |
| No change                                   | 25 (36.8)                              | 55 (46.6)                     | 20 (40.8)                                       | 27 (29.3) | 0.062   |
| Change in breathlessness after Covid-19     |                                        |                               |                                                 |         |
| (MRC Dyspnoea)                              |                                        |                               |                                                 |         |
| No change                                   | 2 (2.9)                                | 5 (4.2)                       | 2 (4.1)                                         | 2 (2.2)  |         |
| More breathless                             | 32 (47.1)                              | 41 (34.7)                     | 24 (49.0)                                       | 56 (60.9) |         |
| (Missing)                                   | 9 (13.2)                               | 17 (14.4)                     | 3 (6.1)                                         | 7 (7.6)  |         |
| Fatigue level (0 to 10 VAS)                 |                                        |                               |                                                 |         |
| Median (IQR)                                | 5 (2.0 to 7.0)                         | 4 (2.0 to 7.0)                | 5 (2.0 to 7.0)                                 | 5 (2.0 to 7.0) | 0.469 |
| EQ5D-5L change in overall summary index     |                                        |                               |                                                 |         |
| Median (IQR)                                | -0.1 (-0.2 to 0.0)                     | -0.0 (-0.1 to 0.0)            | -0.1 (-0.2 to 0.0)                             | -0.1 (-0.3 to -0.0) | 0.004 |
| Washington Group Short Set                  |                                        |                               |                                                 |         |
| No change in disability                     | 52 (76.5)                              | 88 (74.6)                     | 35 (71.4)                                       | 66 (71.7) | 0.892   |
| New or worse                                | 15 (22.1)                              | 27 (22.9)                     | 13 (26.5)                                       | 24 (26.1) |         |
| (Missing)                                   | 1 (1.5)                                | 3 (2.5)                       | 1 (2.0)                                         | 2 (2.2)  |         |

HFNC—High flow nasal cannulae, NIV—Noninvasive ventilation, MRC—Medical Research Council, IQR—Interquartile range, presented as 25th to 75th centiles. Numbers are presented as N (%), unless otherwise denoted as a continuous variable.
requiring critical care had the worst long-term outcomes even after adjusting for severity of the initial illness. Interestingly, our findings were largely unaffected by existing patient comorbidities or disability. Our findings add considerably to the current literature, as we identify the main risk factor for worse long-term outcomes are being female and under the age of 50. We also have been able to quantify the significant deterioration in disability and breathlessness-related disability in detail. The range of symptoms reported include those which may be related to direct lung damage, such as breathlessness, and also those for which an underlying pathophysiological mechanism may be less clear such as fatigue, muscle pain and cognitive complaints. The latter group are also features of other post infectious syndromes and post intensive care syndrome, and may have a similar aetiology, such as infection triggered autoimmunity, dysautonomia or other mechanism [6-10]. Our study did not make laboratory measurements or collect biological samples as part of the follow-up and hence is not designed to elucidate mechanisms. Future studies which do this will be key to identifying relevant therapeutic targets in long-Covid.

Many of our findings are largely in agreement with other recent studies in other populations globally, which also found high rates of breathlessness and fatigue [4,5]. In the community setting, a recent mobile application-based study, described very high rates of breathlessness (71%) and fatigue (98%) in those reporting symptoms persisting over 28 days [2]. Interestingly, in our population, the presence of symptoms many months after initial infection are higher than the 76% reported by Huang et al. and three times higher than that reported by Munblit et al. There are several reasons why we have found higher rates, which could be related to those responding to each study, or the severity of disease across the different study populations. The Huang et al. and Munblit et al. studies included very small numbers of patients requiring critical care or mechanical ventilation (1% in Huang et al. and under 2-6% in Munblit et al, in contrast to 28-1% 92/327 in our study), suggesting there are significant differences between these populations and our study population; Survivors of general critical illness, independent of baseline disease, may experience persistent breathlessness, fatigue, muscle weakness, and other symptoms of post-intensive care syndrome which cause substantial deficits in quality of life that may persist for many years [10]. There may several reasons for this difference in study population, such as challenges to recruitment of critically unwell patients, differing in-hospital mortality rates, preexisting population comorbidities or pressure on the healthcare systems during the pandemic. Based on data from several countries, the higher rates of participants requiring critical care in our study suggests our data is likely to be more generalisable [30–33].

In our study, being young, female and having a high severity of acute disease were the strongest independent predictors of poor long-term outcomes. It is unclear why females had the worst outcomes. This could be to do with the effects of initial exposure, where females are more likely to be in industries where exposure to SARS-
CoV-2 may be higher [34], however recent data suggests teachers do not have greater exposure than other working-age populations and there is emerging evidence of divergent host responses to SARS-CoV-2 infection [35,36]. Another explanation is that females are more likely to survive severe acute disease than men, so could have worse long-term outcomes as a result. However, in our data, we could not find any differences by sex across several measures of disease severity. A further possibility is that men felt less able or inclined to disclose symptoms. There is some discussion in the literature that recall bias, and also reporting of symptoms may differ between males and females, which may account for some of the gender difference seen – however this would not account for these differences being also related to age as well as gender [37]. From our findings it is clear more research is required into why females have worse long-term outcomes, particularly as sectors where females are likely to have greater exposure to SARS-CoV-2 are beginning to reopen (e.g. education, hospitality and healthcare).

There are several limitations to our study. First, we were not able to follow all the cases that were discharged from hospital, either because they did not give permission or because they did not respond to repeated requests for information. We attempted to reach non-responders to the survey via telephone follow-up to limit potential for selection bias, but not all could be reached. However the 73% response rate is substantially above the expected response rate for multi-modal questionnaires (60%) [38]. It is possible that those who did not respond might have been well and therefore uninterested in responding, but it could also be that some were too unwell to respond, had died or moved away. Our results may therefore not be fully representative of the entire population of those hospitalised with Covid-19. The potential completion bias may have led to over representation of the prevalence of people affected by long Covid, but may also be underrepresenting people from different demographics. Nevertheless, the data shows that amongst the cohort of people that consented to be contacted post Covid-19 hospital discharge, a large proportion were not fully recovered from Covid more than three months post discharge. This is similar to what has been reported in other countries [4,5].

Secondly, we did not include patients hospitalised with other non-Covid-19 illness or a contemporaneous control group, therefore it is unknown if the changes in our outcomes e.g. quality of life, are specific to recovery from Covid-19 or may be linked to other aspects of life during the pandemic. The study used to generate this data (ISA-RIC WHO Clinical Characterisation Protocol/CCP-UK) is a prospective pandemic preparedness protocol which is agnostic to disease and has a pragmatic design to allow recruitment during pandemic conditions. Thirdly, patients only completed the survey at one timepoint, limiting comparison across repeat measures. This also meant retrospective measures asking patients to rate outcomes before their Covid-19 illness were included, which are open to recall bias. Fourth, the differences in collecting data (in clinic, by post, by telephone) may add to heterogeneity in the data. Finally, as our study focussed on hospitalised patients primarily from the first wave of infection in the UK, our data cannot be generalised to those with disease managed in the community who comprise the majority of individuals affected by Covid-19.

Future research should focus on establishing the optimal care of this cohort, identifying interventions to test in randomised trials and to identify the mechanisms underlying adverse long-term outcomes. The PHOSP-Covid (Post-HOSPitalisation Covid-19) study is ongoing and will inform patient care by adding to our data on the long-term sequelae of Covid-19, looking at the impact on these of acute and post-discharge interventions, and exploring possible mechanisms including measurement of laboratory parameters and functional diagnostics [39].
population health and wellbeing. The data highlights an urgent need for long-Covid symptoms and the potential long-term impact on mortality and wellbeing. Moreover, the long-term effects of Covid-19 are determined by factors that differ from those that predict increased mortality. Participants reported significant difficulties, including increased breathlessness, new or worsened disability and other health issues.

### Table 3

Multilevel regression models for secondary outcomes of new or persistent symptoms, change in MRC dyspnoea scale, fatigue, EQSD-5L summary index change and Washington Short Set new or worse disability.

| Explanatory variable | New or persistent symptoms: OR (95% Confidence Interval) | Change in MRC Dyspnoea: OR (95% Confidence Interval) | Fatigue level: Coefficient (95% Confidence Interval) | EQSD-5L summary index change: Coefficient (95% Confidence Interval) | Washington Short Set new or worse disability: OR (95% Confidence Interval) |
|-----------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| **Sex at Birth by Age** | | | | | |
| Male | Under 50 | 0.82 (0.21-3.30, p=0.783) | 2.20 (0.89-5.45, p=0.088) | 0.44 (-0.56 to 1.44, p=0.94) | -0.05 (-0.11 to 0.02, p=0.903) | 1.66 (0.51-5.42, p=0.401) |
| Male | 50 to 69 | 0.74 (0.14-3.83, p=0.720) | 2.59 (0.84-7.95, p=0.095) | 0.38 (-0.84 to 1.60, p=0.727) | -0.04 (-1.20 to 0.14, p=0.84) | 2.08 (0.55-7.96, p=0.283) |
| Female | Under 50 | 2.75 (0.26-28.92, p=0.001) | 7.15 (2.24-22.83, p=0.001) | 2.06 (0.81 to 5.31, p=0.001) | -0.19 (-2.70 to -0.01, p=0.034) | 4.22 (1.12-15.94, p=0.034) |
| Female | 50 to 69 | 2.10 (0.39-11.37, p=0.389) | 6.18 (2.28-16.78, p=0.001) | 1.00 (0.15 to 2.24, p=0.012) | -0.10 (-1.70 to -0.01, p=0.000) | 2.79 (0.81-9.03, p=0.017) |
| **Any comorbidity** | | | | | |
| No comorbidities | | | | | |
| One or more comorbidities | 2.28 (0.92-5.65, p=0.076) | 0.74 (0.42-1.31, p=0.304) | 0.95 (0.35 to 1.55, p=0.001) | -0.02 (-0.06 to 0.02, p=0.139) | 2.96 (1.57-5.57, p=0.001) |
| **Severity** | | | | | |
| Scale 3 (did not receive supplemental oxygen) | | | | | |
| Scale 4 (received supplemental oxygen) | 0.61 (0.15-2.43, p=0.483) | 0.51 (0.24-1.07, p=0.076) | -0.26 (-1.06 to 0.55, p=0.266) | 0.04 (-0.01 to 0.09, p=0.977) | 1.11 (0.51-2.40, p=0.798) |
| Scale 5 (received HFNC or NIV) | 0.32 (0.07-1.46, p=0.142) | 0.89 (0.36-2.21, p=0.794) | -0.20 (-1.22 to 0.83, p=0.354) | 0.01 (-0.06 to 0.08, p=0.371) | 1.32 (0.49-3.51, p=0.583) |
| Scale 6 or 7 (received invasive mechanical ventilation or critical care) | 1.18 (0.24-5.95, p=0.838) | 1.02 (0.79-4.22, p=0.162) | -0.18 (-1.09 to 0.74, p=0.354) | -0.05 (-1.11 to 0.09, p=0.073) | 1.48 (0.63-3.52, p=0.370) |

HFNC – High flow nasal cannulae, NIV – Noninvasive ventilation, MRC – Medical Research Council. Model metrics: For persistent symptoms - Number in model = 327, Number of groups = 32, AIC = 172.4, C-statistic = 0.683; For change in MRC dyspnoea level - Number in model = 291, Number of groups = 32, AIC = 383.1, C-statistic = 0.767; For change in fatigue - Number in model = 308, Number of groups = 32, Log likelihood = -724.13, RELM criterion = 1448.3; For change in health state (EQSD-5L) - Number in model = 311, Number of groups = 32, Log likelihood = 80.55, RELM criterion = -161.1; For change in Washington short set disability - Number in model = 320, Number of groups = 31, AIC = 355.1, C-statistic = 0.74.

5. Conclusion

In our study of 327 patients who were discharged alive from hospital, we found most participants reported symptoms months after acute Covid-19 infection. The most common symptoms were fatigue and breathlessness. Participants reported significant difficulties, including increased breathlessness, new or worsened disability and worse quality of life following Covid-19. These symptoms were largely independent of age and prior comorbidity, suggesting that the long-term effects of Covid-19 are determined by factors that differ from those that predict increased mortality. Moreover, the high frequency and severity of long-term symptoms emphasise the importance of long-Covid symptoms and the potential long-term impact on population health and wellbeing. The data highlights an urgent need for access to comprehensive assessments for people living with long Covid, including complex diagnostics to identify aetiology and inform appropriate treatment to improve long term Covid-19 outcomes.

^ISARIC Global Covid-19 follow up working group: Adam Ali, John H Amuasi, Andrea Anghelius, John Kenneth Baille, Valeria Balan, Ibrahim Richard Bangura, Anna Beltrame, Frank Bloos, Lucille Blumberg, Fernando Bozza, Danilo Buonsenso, Caterina Caminiti, Gail Carson, Daniel Cassaglia, Muge Cevik, Allegra Chatterjee, Nina Jamieson, Waasila Jassat, Edwin Jesudason, Anders Benjamin, Lucille Blumberg, Fernando Bozza, Danilo Buonsenso, Caterina Caminiti, Gail Carson, Daniel Cassaglia, Muge Cevik, Allegra Chatterjee, Nina Jamieson, Waasila Jassat, Edwin Jesudason, Anders Benjamin.\n
---

**Fig. 5.** Multilevel model for primary outcome of self-reported recovery (reference level is feeling fully recovered)
Kidal, Sulaiman Lakoh, Nicola Latronico, James Lee, Wei Shen Lin, Sam Lissaure, Nazir Lone, David J Lowe, Sinnadurai Manohan, Romans Matulevics, Joanne McPeake, Laura Merson, Roberta Meta, Melina Michelen, Sarah Moore, Ben Morton, Caroline Mudura, Daniel Munblit, Srinivas Murthy, Behzad Najjam, Ebrahim Ndure, Nikita Neklidov, Piero Oliaro, Carlo Palmeri, Prasan K Panda, Simone Piva, David J Plotkin, Matteo Puntini, Jordi Rello, Liliana Resende, Luis Felipe Reyes, Ishmeala Riba, Sergio Ruiz Saltana, Clark D Russell, Steffi Ryckaert, Janet T Scott, Malcolm G Semple, Louise Sigfrid, Girish Sindhwa Pulm, Arne Sørøas, Renaud Tamisier, Lance Turtle, Caroline Vika, Natalie Wright

^ISARIC4C investigators Consortium lead investigator:
J Kenneth Baillie, Malcolm G Semple, Peter JM Ospenshaw; Gail Carson, Benjamin Bach, Wendy S Barclay, Debby Bogaert, Meera Chand, Graham S Cooke, Annemieke B Docherty, Jason Dunning, Anna da Silva Filipe, Tom Fletcher, Christophe A Green, Ewen M Harrison, Julian A Hiscox, Antonia Ying Wai Ho, Peter W Horby, Samreen Ijaz, Saye Khoo, Paul Klenerman, Andrew Law, Wei Shen Lin, Alexander J Mentzler, Laura Merson, Alison M Meynert, Mahdad Nouraddeghi, Shona C Moore, Massimo Palmarini, William A Paxton, Georgios Pollakis, Nicholas Price, Andrew Rambaut, David L Robertson, Clark D Russell, Vanessa Sancho-Simizu, Janet T Scott, Thushan de Silva, Louise Sigfrid, Tom Solomon, Shiranee Sriskanand, David Stuart, Charlotte Summers, Richard S Tedder, Emma C Thomson, AA Roger Thompson, Ryan S Thwaites, Lance CW Turtle, Rishi K Gupta, Carlo Palmeri, Maria Zambon, Chloe Donohue, Ruth Lyons, Fiona Griffiths, Wilna Oosthuyzen, Riinu Pius, Thomas M Drake, Cameron J Fairfield, Stephen R Knight, Kenneth A Mclean, Derek Murphy, Catherine A Shaw, Michelle Girvan, Egle Savicuhte, Stephanie Roberts, Janet Harri-son, Laura Marsh, Marie Connor, Sophie Halpin, Clare Jackson, Carrol Gamble, Andrew Law, Murray Wham, Sara Clohisey, Ross Hendry, James Scott-Brown, Victoria Shaw, Sarah E McDonald, Jane A Arm-strong, Martin Ashworth, Innocent G Asimwe, Siddharth Baboki, Samantha L Barlow, Laura Booth, Benjamin Brennan, Katie Bullock, Benjamin WA Caterall, Jordan J Clark, Emily A Clarke, Sarah Cole, Louise Cooper, Helen Cox, Christopher Davis, Oslem Dincarlsen, Chris Dunn, Philip Dyer, Angela Elliott, Anthony Evans, Lorna Finch, Lewis WS Fisher, Terry Foster, Isabel Garcia-Dorival, William Greenhalph, Philip Gunnung, Catherine Hartley, Rebecca L Jensen, Christopher B Jones, Trevor R Jones, Shadia Khardaker, Katharine King, Robyn T Kiy, Chrysa Koukorava, Anitha Lant, Dianne Lattawich, Carolann Lavelle-Lamph, Daniella Lefteri, Lauren Lett, Lucia A Livoti, Maria Mancini, Sarah McDonald, Laurence McEvoy, John McLauchlan, Soe- ren Metelmann, Nahida S Miah, Joanna Middleton, Joyce Mitchell, Shona C Moore, Ellen G Murphy, Rebekah Penrice-Randall, Jack Pilgrim, Tessa Prince, Will Reynolds, P. Matthew Ridley, Debby Sales, Victoria E Shaw, Rebecca K Shears, Benjamin Small, Krishanti S Subramaniam, Agnieszka Szemiel, Aislynn Taggart, Jolanta Tanianis-Victoria E Shaw, Rebecca K Shears, Benjamin Small, Krishanti S Subramaniam, Agnieszka Szemiel, Aislynn Taggart, Jolanta Tanianis-Hughes, Jordan Thomas, Erwan Trochou, Libby van Tonder, Eve Wilcock, J. Eunice Zhang, Lisa Flaherty, Nicole Maziere, Emily Cass, Alec-lendria Doce Carracedo, Nicola Carlucci, Anthony Holmes, Hannah Massey, Nicola Wrobak, Sarah McCafferty, Kirstie Morriss, Alan MacLean, Daniel Agranoff, Ken Agwu, Dhiraj Ali, Erin L Alder, Ana Alegrina, Brian Angus, Abdul Ashish, Dougal Atkinson, Shahedal Bari, Gavin Barlow, Stella Barnsma, Nicholas Barrett, Christopher Bassford, Sneha Basude, David Baxter, Michael Beadsworth, Jolanta Bernatoniene, John Berridge, Nicole Best, Peter Bothma, David Chadwick, Robin Brittain-Lang, Naomie Bulteel, Tom Burden, Andrew Burtenshaw, Vikki Caruth, David Chadwick, Duncan Chambler, Nigeel Chee, Jenny Child, Srikanth Chukkambotla, Tom Clark, Paul Collini, Catheri-ne Cosgrove, Jason Coupit, Maria-Teresa Cutino-Moguel, Paul Dark, Chris Dawson, Samir Dervisvice, Phil Donnison, Sam Douthwaite, Ingrid Durand, Aihalanedan Dushianthan, Tristan Dyer, Cariad Evans, Chi Eziefula, Christopher Fegan, Adam Finn, Duncan Fullerton, Sanjeev Garg, Sanjeev Garg, Atul Garg, Effrossyni Gkrania-Klotsas, Jo Godden, Arthur Goldsmith, Clive Graham, Elaine Hardy, Stuart Hartshorn, Daniel Harvey, Peter Havaldaka, Daniel B Hawcutt, Maria Hobrok, Luke Hodgson, Anil Hormis, Michael Jacobs, Susan Jain, Paul Jennings, Agi-lan Kaliapan, Vidya Kasipandan, Stephen Kegg, Michael Kelsey, Jason Kendall, Caroline Kerrison, Ian Kerslake, Oliver Koch, Gouri Koduri, George Koshy, Shondipon Laha, Steven Laird, Susan Larkin, Tamas Leiner, Patrick Lillie, James Limb, Vanessa Linnett, Jeff Little, Mark Lyttle, Michael MacMahon, Emily MacNaughton, Ravish Man-krogod, Huw Masson, Eliyah Matouv, Katherine McCullough, Ruth McEwen, Manjula Meda, Gary Mills, Jane Minton, Marjym Mirfen-deresky, Kayya Mohandas, Quen Mok, James Moon, Elinnoor Moore, Patrick Morgan, Craig Morris, Katherine Mortimore, Samuel Moses, Mbye Mpenge, Rohinton Mulla, Michael Murphy, Megan Nagel, Tha-pas Nagarajan, Mark Nelson, Matthew K. O’Shea, Igor Otahal, Marlies Ostermann, Mark Pais, Selva Panchatsharam, Danai Papakonstanti-nou, HassanParaibo, Brij Patel, Natalie Pattinson, Justin Pepperell, Mark Peters, Mandeep Phull, Stefania Pintus, Jagtir Singh Pooni, Frank Post, David Price, Rachel Prout, Nikolas Rae, Henrik Reschtreiter, Tim Reynolds, Neil Richardson, Mark Roberts, Devender Roberts, Alis-tair Rose, Guy Rousseau, Brendan Ryan, Taranprit Saluja, Aarti Shah, Prad Shannmuga, Anil Sharma, Anna Shawcross, Jeremy Sizer, Manu Shankar-Hari, Richard Smith, Catherine Snelson, Nick Spittle, Nikki Staines, Tom Stambach, Richard Stewart, Pradeep Subudhi, Tamas Szakmany, Kate Tatham, Jo Thomas, Chris Thompson, Robert Thom-spon, Ascanio Tridente, Darelle Tupper-Carey, Mary Twagira, Andrew Ustianowski, Nick Villotton, Lisa Vincent-Smith, Shico Visuvanathan, Alan Vuyelitseke, Sam Waddy, Rachel Wake, Andrew Walden, Ingeborg Welters, Tony Whitehouse, Paul Whittaker, Ashley Whittington, Pat-maseaee Papineni, Meme Wjsinghe, Martin Williams, Lawrence Wilson, Sarah Cole, Stephen Winchester, Martin Wiselka, Adam Wольson, Daniel G Wootton, Andrew Workman, Bryan Yates, Peter Young.

Author contributors
JTS, LS, MGS developed the concept of the follow up study. JTS, LS, LWS, TMD, EJ, WLS, CR, DJL, MC, JMCP, NL, EMH, DM, CR, AH, LT, PB, and the ISARIC Global Covid-19 follow up working group developed the follow up protocol and methodology. ISARIC4C investigators identified participants during the acute admission and entered acute phase data. PB, CD, HH, RS, JH, AG coordinated follow up survey distribution, data entry, AG, AC, LG conducted telephone follow up. LS, JTS, GC, HH coordinated resources. LS, JTS, TMD, EP, AD, PO, EH, ABD were involved in data visualisation. TMD, EP, LS, JTS, MEOH, PJMO, CH, CEH, JKB, ABD. MGS analysed and interpreted the data. LS, TMD, EP, JTS wrote the original draft of the manuscript. All authors reviewed, and revised the manuscript prior to submission. JTS is the guarantor.

Declaration of Interests
CRD declares funding from the Medical Research Council, UK. JM reports a University of Cambridge Research Fellowship. WSL reports unrestricted investigator-initiated research funding from Pfizer for an unrelated multi-centre study in pneumonia, in which WSL is the CI and UK NIHR research funding for unrelated clinical trials in the fields of COVID-19, tuberculosis and community-acquired pneumonia. WSL’s role on the Joint Committee on Vaccination and Immunisation (JCVI), UK and chair of COVID-19 Immunisation and as National Lead on British Thoracic Society community acquired pneumonia audit programme is unpaid and unrelated to this work. CB declares a British Heart Foundation Centre award, and a project grants from the Chief Scientist Office, Scottish Government CSO Long Term Effects and from Heart Research UK unrelated to this work. LG declares support from Pfizer & Gilead for attendance at an educational meeting in Nov 2018 and April 2019, for cost of conference registration fee, accommodation and flights unrelated to this work. PJMO reports personal fees from consultancy, grants from MRC, EU, NIHR Biomedical
Acknowledgements
This work uses data provided by patients and collected by the NHS as part of their care and support #DataSavesLives. We are extremely grateful to the 2,648 frontline NHS clinical and research staff and volunteer medical students, who collected this data in challenging circumstances; and the generosity of the participants and their families for their individual contributions in these difficult times. In particular, the ISARIC Global Covid-19 Follow up working group and the ISARIC global support centre. We would also like to acknowledge the support of Jeremy J Farrar.

Ethical approval
Ethical approval was given by the South Central – Oxford C Research Ethics Committee in England (ref 13/SC/0149) and the Scotland A Research Ethics Committee (ref 20/SS/0028).

Data sharing statement
Data are available for reuse through a secure data sharing platform. Access is welcome through the ISARIC Independent Data and Material Access Committee (https://isaric4c.net).

Transparency
The lead author (the manuscript’s guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Dissemination plans
Dissemination to participants and related patient and public communities: ISARIC4C has a public facing website [ISARIC4C.net] and twitter account (@CCPUKstudy). We are engaging with print and internet press, television, radio, news, and documentary programme makers.

Funding statement
This work is supported by grants from: the National Institute for Health Research (NIHR) [award CO-CIN-01], the Medical Research Council [grant MC_PC_19059], the Imperial Biomedical Research Centre (NIHR Imperial BRC, grant P45058), the Health Protection Research Unit (HPRU) in Respiratory Infections at Imperial College London and NIHR HPRU in Emerging and Zoonotic Infections at University of Liverpool, both in partnership with Public Health England, [NIHR award 200907], Wellcome Trust and Department for International Development [215091/Z/18/Z], and the Bill and Melinda Gates Foundation [OPP1209135], and Liverpool Experimental Cancer Medicine Centre (Grant Reference: C18616/A25153), NIHR Biomedical Research Centre at Imperial College London [JS-BRC-1215-20013], EU Platform for European Preparedness Against (Re-) emerging Epidemics [FP7 project 602525] and NIHR Clinical Research Network for providing infrastructure support for this research. LT is a Wellcome Trust clinical career development fellow, supported by grant number 205228/Z/16/Z. This research was funded in part, by the Wellcome Trust. PJMO is supported by a NIHR Senior Investigator Award [Award 201385]. The views expressed are those of the authors and not necessarily those of the DHSC, DID, NIHR, MRC, the Wellcome Trust or PHE.

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi:10.1016/j.lanepe.2021.100186.

References
[1] Carli A, Bernabei R, Landi F, Group for the GAC-19 P-ACS. Persistent Symptoms in Patients After Acute COVID-19. JAMA 2020;324:603–5.
[2] Sudre CH, Murray R, Varasavsky T, et al. Attributes and predictors of long COVID. Nat Med 2021. doi: 10.1038/s41591-021-01192-y.
[3] Salehi S, Reddy S, Cholmusreeanachud A, Long-term Pulmonary Consequences of Coronavirus Disease 2019 (COVID-19): What We Know and What to Expect. J Thorac Imaging 2020;35:8W9–7.
[4] Mubiru D, Bubuoka P, Spuridonova E, et al. Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study. medRxiv 2021.02.17.21251895.
[5] Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220–32.
[6] Surki TK. Post-Ebola syndrome. Lancet Infect Dis 2016;16:780–1.
[7] Scott JT, Sesay FR, Massaquoi TA, Idriss BR, Sahr F, Semple MG. Post-Ebola Syndrome, Sierra Leone. Emerg Infect Dis 2016;22:641–6.
[8] Hung TM, Wills B, Clapham HE, Yacoob S, Turner HC. The Uncertainty Surrounding the Burden of Post-acute Consequences of Dengue Infection. Trends Parasitol 2019;35:673–6.
[9] Blettery M, Brunier L, Polomant K, et al. Brief Report: Management of Chronic Post-Chikungunya Rheumatic Disease: The Martinican Experience. Arthritis Rheumatol 2016;68:2817–24.
[10] Rawal G, Yadav S, Kumar R. Post-intensive care syndrome: An overview. J Transl Intern Med 2017;5:90–2.
[11] NICE. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE Guidel. [NG188]: 2020 https://www.nice.org.uk/guidance/ng188 accessed March 10, 2020.
[12] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
[13] Verity R, Kelik CI, Dorigati I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020;20:669–77.
[14] Clark A, J M, Warren-Gash C, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Heal 2020;8:E1003–17.
[15] National Institute for Demographic Studies. Demographics of COVID-19 deaths: data and metadata. Covid-19 INED. https://dc-covid.site.ined.fr/en/data/ accessed March 10, 2020.
[16] Global Health 50/50. COVID-19: data disaggregated by age and sex. https://globalhealth5050.org/covid19/age-and-sex-data/ accessed March 12, 2020.
[17] Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ 2020;370:m3339.
[18] Latronico N, Pelis E, Rodella F, Novelli MP, Ranulo FA, Piva S. Three-Month Outcome in Survivors of COVID-19: An Associated Acute Respiratory Distress Syndrome. Preps with Lancet 2021. doi:10.2139/ssrn.3749226.
[19] The Lancet. Facing up to long COVID. Lancet 2020;396:1861.
[20] ISARIC. ISARIC Clinical Characterisation Protocol (CCP); UK version. https://isaric4c.net/protocol/ accessed Feb 1, 2020.
[21] ISARIC. WHO–ISARIC–4C Global. https://isaric4c.net/research/covid-19-clinical-research-resources-clinical-characterisation-protocol-ccp/ accessed Feb 1, 2020.
[22] von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. J Clin Epidemiol 2008;61:344–9.
[23] Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020;20:192–7.
[24] Gupta RK, Harrison EM, Ho A, et al. Development and validation of the ISAR- 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respir Med 2021;0. doi:10.1016/S2213-2600(21)00355-2.
[25] Washington Group on Disability Statistics. The Washington Group Short Set on Functioning (WG-SS). WG-SS. https://www.washingtongroupdisability.com/question-sets/wg-short-set-on-functioning-wg-ss/ accessed Feb 1, 2020.
[26] Medical Research Council. 1952 MRC Breathlessness Scale. https://mrc.ukri.org/research/facilities-and-resources-for-researchers/mrc-scales/mrc-dyspnoea-scale-mrc-breathlessness-scale/(accessed Feb 1, 2020).
[27] EuroQol Research Foundation. EQ-5D-3L User Guide. https://euroqol.org/publications/user-guides accessed Feb 1, 2020.
[28] Devlin N, Parkin D, Browne J. Using the EQ-5D as a performance measurement tool in the NHS. Health Econ 2010;19:886–905.
[29] Parkin D, Devlin N, Rice N. Statistical analysis of EQ-5D profiles: does the use of value sets bias inference? Med Decis Making 2010;30:556–65.
[30] Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020;369:m1985.
[31] Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020;369:m1985.
[32] Abate S, Ahmed AS, Manifardo B, Basu B. Rate of Intensive Care Unit admission and outcomes among patients with coronavirus: A systematic review and Meta-analysis. PloS One 2020;15:e0235653.
[33] Escher M, Hall M, Bailie JK, et al. ISARIC Clinical Data Report 10 February 2021. medRxiv 2021 2020.07.17.20155218.
[34] Office for National Statistics. Which occupations have the highest potential exposure to the coronavirus (COVID-19)? https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/articles/whicheoccupationshavethehighestpotentialexposuretocoronaviruscovid19/2020-05-11 accessed March 12, 2020.
[35] Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 2020;588:315–20.
[36] Office for National Statistics. COVID-19 Schools Infection Survey Round 2, England: December 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyround2/england/december2020 accessed March 12, 2020.
[37] Fincham Jack E. Response rates and responsiveness for surveys, standards, and the Journal. Am. J. Pharm. Educ. 2008;72:43.
[38] Barsky A, Peekna H, Borous J. Somatic symptom reporting in women and men. J. Gen. Intern. Med. 2001;16:266–75.
[39] PHOSP Covid. Long-term follow up of adults hospitalised with COVID-19. Prospectively registered. ISRCTN Regist 2020.